FDA Determines Regulatory Review Period for HINTERMANN SERIES H3 Total Ankle Replacement System

Summary

The U.S. Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the HINTERMANN SERIES H3 Total Ankle Replacement System, a medical device, as a result of a patent extension application submitted to the U.S. Patent and Trademark Office (USPTO).